// App-Quantinova.ai

5069 : Clinical outcomes and safety of enzalutamide (ENZA) plus androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) in patients aged < 75 and ≥ 75 years ARCHES post hoc analysis.

Researchers

Presenter

  • Russell Zelig Szmulewitz

Principal Investigators

  • Jeffrey Holzbeierlein

  • Arun Azad

  • Taro Iguchi

  • Arnauld Villers

  • Antonio Alcaraz

  • Boris Alekseev

  • Neal D. Shore

  • Brad Rosbrook

  • Fabian Zohren

  • Jie Ma

  • Gabriel P. Haas

  • Francisco Gomez-Veiga

  • Arnulf Stenzl

  • Andrew J. Armstrong

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • University of Kansas Medical Center, Kansas City, MO

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Kanazawa Medical University, Uchinada, Japan

  • University Hospital Centre, Lille University, Lille, France

  • Hospital Clinic Barcelona, Barcelona, Spain

  • P.A. Herzen Moscow Cancer Research Institute, Moscow, Russia

  • Carolina Urologic Research Center, Myrtle Beach, SC

  • Pfizer Inc, New York, NY

  • Pfizer Inc, San Diego, CA

  • Astellas Pharma, Inc., Northbrook, IL

  • Complejo Hospitalario Universitario de A Coruna, A Coruna, Spain

  • University Hospital, Eberhard Karls University, Tübingen, Germany

  • Duke Cancer Institute Center for Prostate and Urologic Cancer, Duke University School of Medicine, Durham, NC

Locations

  • United States

  • Australia

  • Japan

  • France

  • Spain

  • Russia

  • Germany

Companies

  • PharmAbcine Inc.

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Urology

  • Oncology (ONC)

Disease

  • Prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02677896

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved